MDWD at a glance
MediWound Ltd. (MDWD, SEC CIK 1593984) filed its latest 20-F annual report on March 5, 2026, a 6-K report on November 12, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding MediWound Ltd. (MDWD) shares worth $25.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Rubinstein Samuel on September 1, 2026 of 525 shares at $12.72 per share.
- In the last 90 days, MDWD insiders reported 1 open-market purchase ($7K) and 4 open-market sales ($82K) on Form 4, a net sale of $75K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 1 buy · 4 sells
- Net −$75K
- 13F holders
- 16 funds
- $25.8M · +0 vs prior quarter
- Latest 6-K
- Nov 12, 2026
- Foreign issuer report
AI 20-F Annual Report Analysis
Latest 20-F, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development and commercialization of enzymatic therapeutics for non-surgical tissue repair, focusing on burn and chronic wound care
- New emphasis on EscharEx pivotal Phase III VALUE trial (216 patients, US and Europe), plus planned Phase II DFU and pressure ulcer studies in 2026
- Strategic sixfold increase in NexoBrid manufacturing capacity completed Nov 2025 to meet growing global demand
- Funding: $3.6M additional DoW support for temperature-stable NexoBrid formulation development; secured €2.5M European grant for EscharEx DFU clinical advancement
- Noteworthy: NexoBrid approved now in 45 countries including Australia (2025 approval); EscharEx peak sales estimated at $831M by independent firm
Management Discussion & Analysis
- Revenue $17.0M in 2025 vs $20.2M in 2024, down 16% primarily due to U.S. government shutdown and lower Vericel product sales
- Operating loss increased to $25.3M in 2025 from $19.4M in 2024; gross margin improved to 19.2% in 2025 (gross profit $3.3M) vs 13.0% (gross profit $2.6M) in 2024
- Best segment: Development services $10.8M (-18% YoY); Worst: Product sales $5.8M (-15% YoY) mainly from Vericel downturn
- Cash flow: Operating cash outflow $16.1M in 2025 vs $13.6M in 2024; Investing outflow $18.0M vs $8.4M (capex and deposits); Financing inflow $29.6M vs $19.4M (equity raises and warrants)
- Outlook: Cash of $53.6M as of Dec 2025 sufficient for 12+ months; plans to invest in EscharEx Phase III; recognizes ongoing R&D losses and potential need for additional funding
Risk Factors
- Regulatory delay risk: New EU Clinical Trials Regulation effective Jan 31, 2025, centralized trial applications replacing prior national processes
- Geopolitical exposure: Sole supplier bromelain SP facility in Taiwan threatened by China-Taiwan tensions impacting raw material supply
- Operational vulnerability: Single manufacturing site in Yavne, Israel, faces shut down risk from war, terrorism or natural disasters
- Competitive risk: Competition from Smith & Nephew Plc’s collagenase-based SANTYL for enzymatic debridement in chronic wounds
- Financial risk: Net loss $23.9M in 2025 with accumulated deficit $228.9M, requiring additional capital potentially causing shareholder dilution
AI summary of the MDWD 20-F filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
SignalX for MDWD
Don't miss the next MDWD filing
- Alerts as it files. A push when MDWD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MDWD, by share count.
- Ask anything. An AI agent that reads every MDWD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gonen Ofer | X | Nov 11, 2026 | 8,168 | $13.47 |
| Gonen Ofer | X | Nov 11, 2026 | 8,168 | - |
| Fox David Morton | X | Nov 10, 2026 | 6,534 | - |
| Fox David Morton | X | Nov 10, 2026 | 6,534 | $13.47 |
| SHAMIR NACHUM | X | Nov 10, 2026 | 16,336 | - |
| SHAMIR NACHUM | X | Nov 10, 2026 | 16,336 | $13.47 |
| Rubinstein Samuel | Sell | Sep 1, 2026 | 525 | $12.72 |
| Rubinstein Samuel | Buy | Sep 1, 2026 | 525 | $12.62 |
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MDWD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 16 | $25.8M |
| Q2 2026 | 16 | $28.5M |
| Q1 2026 | 14 | $29.2M |
| Q4 2025 | 16 | $32.2M |
| Q3 2025 | 15 | $30.4M |
| Q2 2025 | 16 | $26.9M |
| Q1 2025 | 13 | $7.7M |
| Q4 2024 | 11 | $8.8M |
- ARK Investment Management+20.1K (+16%)
- Morgan Stanley+18.7K (+21%)
- BlackRock+8.1K (+2%)
- Invesco Ltd+3.0K (+24%)
- T. Rowe Price Group+2.5K (+0%)
- AQR Capital Management−28.9K (-57%)
- Goldman Sachs Group−21.0K (-63%)
- Northern Trust−12.0K (-11%)
- Wells Fargo & Co−6.3K (-38%)
- Citigroup−3.8K (-78%)
- Citadel Advisors LLC−58.5K
- FMR LLC (Fidelity)−5.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 117 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 20-F, 6-K
Related Health Care companies
- BTMD · biote Corp.Medicinal Chemicals & Botanical Products
- DFTX · Definium Therapeutics, Inc.Medicinal Chemicals & Botanical Products
- FTLF · FITLIFE BRANDS, INC.Medicinal Chemicals & Botanical Products
- NAGE · Niagen Bioscience, Inc.Medicinal Chemicals & Botanical Products
- USNA · USANA HEALTH SCIENCES INCMedicinal Chemicals & Botanical Products
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
MDWD SEC filings: frequently asked questions
Are MDWD insiders buying or selling?
In the last 90 days, MediWound Ltd. (MDWD) officers, directors and 10% owners reported 1 open-market purchase worth $6,626 by 1 insider and 4 open-market sales worth $82,072 by 2 insiders on Form 4, a net sale of $75,447. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MDWD stock?
As of September 30, 2026, the largest MediWound Ltd. (MDWD) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($8.9 million), BlackRock ($7.4 million), State Street Corp ($2.3 million), ARK Investment Management ($2.0 million), Morgan Stanley ($1.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in MDWD's latest 20-F?
In the 20-F filed March 5, 2026, MediWound Ltd. (MDWD) flagged: Regulatory delay risk: New EU Clinical Trials Regulation effective Jan 31, 2025, centralized trial applications replacing prior national processes. Geopolitical exposure: Sole supplier bromelain SP facility in Taiwan threatened by China-Taiwan tensions impacting raw material supply. (AI summary of the Risk Factors section.)
What are the latest MDWD SEC filings?
MediWound Ltd. (MDWD) filed its latest 20-F annual report on March 5, 2026, a 6-K report on November 12, 2026 and a Form 4 insider filing on November 12, 2026.
What is MDWD's SEC CIK number?
MediWound Ltd. (MDWD)'s SEC Central Index Key (CIK) is 1593984. EDGAR lists every MDWD filing under that number.
Ask anything about MDWD
The research agent reads MDWD's filings, financials, insider trades and 13F holders, then answers with sources.